Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves
Post# of 341
(Total Views: 281)
Posted On: 11/19/2021 5:15:40 PM
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health
- Company releases positive results from preclinical study focusing on psilocybin program CYB003
- Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare
- Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration
According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://nnw.fm/Vn2h0). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs (https://nnw.fm/cWQSv).
“Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin CEO Doug Drysdale. “Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB002, and CYB003.”
According to the company, positive CYB003 preclinical findings demonstrate distinctive advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. Those results “may have wide-reaching implications for the treatment of MDD, as well as alcohol use disorder (‘AUD’), with less patient variability, faster onset of action, shorter duration of effect and improved brain penetration,” the company reported.
According to previous research, oral psilocybin appears to be efficacious in treating mental health disorders, especially MDD, but the treatment does have significant limitations, including slow onset of action, extended duration of effect and a variability in response among patients. Cybin’s CYB003 program is designed to maintain the benefits of oral psilocybin while addressing the challenges.
Based on its multispecies, preclinical studies, Cybin has been able to do just that. The company’s CYB003 program showed faster onset of action equates to less down time in the clinic before effects begin; half the duration of effect translates to shorter clinic days or more patients per day; more predictable dose effects create a safer and more effective patient response; lowered peripheral exposure diminishes the risk of nausea; and better brain penetration suggests lower overall dose needed to achieve clinical efficacy.
“While we are all encouraged by the benefits of psilocybin, we need to transparently and openly discuss its limitations if we are to translate psychedelics to therapeutics for patients in need,” said Drysdale. “The majority of current clinical studies are based on psilocybin. We have taken the necessary steps to potentially unlock the powerful benefits of psychedelics and engineer a superior molecule as demonstrated by the data. We are on a mission to make ethical, safe scientific progress to advance the care and treatment of mental health patients. Our goal has always been to be a leader in creating the best therapy for patients; today, we move one step closer.”
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Company releases positive results from preclinical study focusing on psilocybin program CYB003
- Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare
- Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration
According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://nnw.fm/Vn2h0). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs (https://nnw.fm/cWQSv).
“Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin CEO Doug Drysdale. “Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB002, and CYB003.”
According to the company, positive CYB003 preclinical findings demonstrate distinctive advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. Those results “may have wide-reaching implications for the treatment of MDD, as well as alcohol use disorder (‘AUD’), with less patient variability, faster onset of action, shorter duration of effect and improved brain penetration,” the company reported.
According to previous research, oral psilocybin appears to be efficacious in treating mental health disorders, especially MDD, but the treatment does have significant limitations, including slow onset of action, extended duration of effect and a variability in response among patients. Cybin’s CYB003 program is designed to maintain the benefits of oral psilocybin while addressing the challenges.
Based on its multispecies, preclinical studies, Cybin has been able to do just that. The company’s CYB003 program showed faster onset of action equates to less down time in the clinic before effects begin; half the duration of effect translates to shorter clinic days or more patients per day; more predictable dose effects create a safer and more effective patient response; lowered peripheral exposure diminishes the risk of nausea; and better brain penetration suggests lower overall dose needed to achieve clinical efficacy.
“While we are all encouraged by the benefits of psilocybin, we need to transparently and openly discuss its limitations if we are to translate psychedelics to therapeutics for patients in need,” said Drysdale. “The majority of current clinical studies are based on psilocybin. We have taken the necessary steps to potentially unlock the powerful benefits of psychedelics and engineer a superior molecule as demonstrated by the data. We are on a mission to make ethical, safe scientific progress to advance the care and treatment of mental health patients. Our goal has always been to be a leader in creating the best therapy for patients; today, we move one step closer.”
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼